Dian Diagnostics Director Ye Xiaoping Under CSRC Investigation for Alleged Disclosure Violations Regarding Tigermed Shareholding Changes

Stock News

May 13

Dian Diagnostics Group Co.,Ltd. (300244.SZ) announced that its director, Ye Xiaoping, received a "Case Initiation Notice" from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The CSRC has decided to initiate an investigation into Ye Xiaoping for alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co.,Ltd. ("Tigermed"). It is reported that this investigation pertains to information disclosure matters concerning Ye Xiaoping's historical changes in Tigermed shareholdings. The matter is unrelated to the stock transactions, information disclosures, or business operations of Dian Diagnostics and is not expected to impact the company's normal operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1119586648"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119586648\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119586648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119586648","market":"sh","top_or_hot":-1,"title":"Dian Diagnostics Director Ye Xiaoping Under CSRC Investigation for Alleged Disclosure Violations Regarding Tigermed Shareholding Changes","media":"Stock News","content":"<p>Dian Diagnostics Group Co.,Ltd. (300244.SZ) announced that its director, Ye Xiaoping, received a \"Case Initiation Notice\" from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The CSRC has decided to initiate an investigation into Ye Xiaoping for alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co.,Ltd. (\"Tigermed\"). It is reported that this investigation pertains to information disclosure matters concerning Ye Xiaoping's historical changes in Tigermed shareholdings. The matter is unrelated to the stock transactions, information disclosures, or business operations of Dian Diagnostics and is not expected to impact the company's normal operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dian Diagnostics Director Ye Xiaoping Under CSRC Investigation for Alleged Disclosure Violations Regarding Tigermed Shareholding Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDian Diagnostics Director Ye Xiaoping Under CSRC Investigation for Alleged Disclosure Violations Regarding Tigermed Shareholding Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dian Diagnostics Group Co.,Ltd. (300244.SZ) announced that its director, Ye Xiaoping, received a \"Case Initiation Notice\" from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The CSRC has decided to initiate an investigation into Ye Xiaoping for alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co.,Ltd. (\"Tigermed\"). It is reported that this investigation pertains to information disclosure matters concerning Ye Xiaoping's historical changes in Tigermed shareholdings. The matter is unrelated to the stock transactions, information disclosures, or business operations of Dian Diagnostics and is not expected to impact the company's normal operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"","article_id":"1119586648","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119586648","pubTimestamp":1778675420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dian Diagnostics Group Co.,Ltd. (300244.SZ) announced that its director, Ye Xiaoping, received a \"Case Initiation Notice\" from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300244":"迪安诊断","300347":"泰格医药","BK0070":"员工持股","BK0114":"健康中国","BK0174":"增持","BK1583":"高瓴概念","BK0216":"研究试验","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0146":"智慧医疗","BK0077":"质押式回购","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0028":"国家队","BK0197":"中小创蓝筹","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0236":"卫生","03347":"泰格医药","BK0042":"基因检测","BK0186":"小盘成长"},"translate_title":"迪安诊断董事叶小平涉嫌泰格医药股权变动信披违规被证监会立案调查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300244":1,"300347":1,"03347":1},"content_text":"Dian Diagnostics Group Co.,Ltd. (300244.SZ) announced that its director, Ye Xiaoping, received a \"Case Initiation Notice\" from the China Securities Regulatory Commission (CSRC) on May 12, 2026. The CSRC has decided to initiate an investigation into Ye Xiaoping for alleged violations of information disclosure regulations related to shareholding changes in Hangzhou Tigermed Consulting Co.,Ltd. (\"Tigermed\"). It is reported that this investigation pertains to information disclosure matters concerning Ye Xiaoping's historical changes in Tigermed shareholdings. The matter is unrelated to the stock transactions, information disclosures, or business operations of Dian Diagnostics and is not expected to impact the company's normal operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}